- Home
- TENX vs PYPD Comparison
TENX vs PYPD Comparison
Compare TENX & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- PYPD
- Stock Information
- Founded
- TENX 1967
- PYPD 2008
- Country
- TENX United States
- PYPD Israel
- Employees
- TENX N/A
- PYPD N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- TENX Health Care
- PYPD Health Care
- Exchange
- TENX Nasdaq
- PYPD Nasdaq
- Market Cap
- TENX 11.4M
- PYPD 16.3M
- IPO Year
- TENX N/A
- PYPD 2020
- Fundamental
- Price
- TENX $3.29
- PYPD $3.54
- Analyst Decision
- TENX Strong Buy
- PYPD Buy
- Analyst Count
- TENX 2
- PYPD 2
- Target Price
- TENX $30.00
- PYPD $12.00
- AVG Volume (30 Days)
- TENX 30.1K
- PYPD 4.8K
- Earning Date
- TENX 11-11-2024
- PYPD 11-06-2024
- Dividend Yield
- TENX N/A
- PYPD N/A
- EPS Growth
- TENX N/A
- PYPD N/A
- EPS
- TENX N/A
- PYPD N/A
- Revenue
- TENX N/A
- PYPD N/A
- Revenue This Year
- TENX N/A
- PYPD N/A
- Revenue Next Year
- TENX N/A
- PYPD N/A
- P/E Ratio
- TENX N/A
- PYPD N/A
- Revenue Growth
- TENX N/A
- PYPD N/A
- 52 Week Low
- TENX $2.77
- PYPD $2.95
- 52 Week High
- TENX $61.20
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- TENX 36.17
- PYPD 50.62
- Support Level
- TENX $3.28
- PYPD $3.31
- Resistance Level
- TENX $3.54
- PYPD $3.62
- Average True Range (ATR)
- TENX 0.19
- PYPD 0.18
- MACD
- TENX -0.02
- PYPD 0.01
- Stochastic Oscillator
- TENX 4.00
- PYPD 51.25
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.